Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05160922 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Crizotinib Continuation Clinical Study

StatusActive, Not Recruiting
PhasePhase 4
SponsorPfizer
Started
View on ClinicalTrials.gov ↗

Record History

  1. Site details revised at 1 of 13 sitesv24
  2. Enrollment target: 26 to 27v23
  3. Study sites: 15 to 13
    • Primary and study completion dates: Mar 15, 2028 to Mar 21, 2028
    v22
  4. Re-verified, no change to tracked fieldsv21
  5. Primary and study completion dates: Dec 26, 2026 to Mar 15, 2028
    • Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 80 to confirmed 26
    • Study sites: 16 to 15
    v20
Show 18 earlier versionsHide 18 earlier versions
  1. Site details revised at 1 of 16 sitesv19
  2. Site details revised at 3 of 16 sitesv18
  3. Study sites: 15 to 16v17
  4. Study sites: 14 to 15v16
  5. Study sites: 12 to 14v15
  6. Study sites: 8 to 12v14
  7. Study sites: 7 to 8v13
  8. Site details revised at 2 of 7 sitesv12
  9. Site details revised at 1 of 7 sitesv11
  10. Study sites: 6 to 7v10
  11. Study sites: 5 to 6v9
  12. Study sites: 4 to 5v8
  13. Study sites: 3 to 4v7
  14. Site details revised at 1 of 3 sitesv6
  15. Study sites: 2 to 3v5
  16. Site details revised at 2 of 2 sitesv4
  17. Study sites: 1 to 2v3
  18. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Primary and study completion dates: Dec 30, 2026 to Dec 26, 2026
    • Start date changed from estimate of Dec 31, 2021 to Dec 27, 2021
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this continuation study is to provide continued access to crizotinib treatment for eligible participants from a current Pfizer sponsored crizotinib clinical study that is planned to close.
Trial Details
NCT Number NCT05160922
Lead Sponsor Pfizer
Conditions
(from sponsor)		 NSCLC, ALCL, IMT
Related terms Carcinoma, Non-Small-Cell Lung, Granuloma, Plasma Cell, Lymphoma, Large-Cell, Anaplastic
Enrollment 27 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov